JULIE REMPE: Open Payments
NPI 1740234194 · YORK, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$620 in 38 payments from 14 companies in 2025. Trend: 2023 $825 · 2024 $726 · 2025 $620
Food & beverage: $620
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $300 |
| Novo Nordisk Inc | 3 | $52 |
| Lilly USA, LLC | 3 | $44 |
| KYOWA KIRIN, INC. | 2 | $37 |
| Astellas Pharma US Inc | 1 | $34 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| ACADIA Pharmaceuticals Inc | 1 | $16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
Products named: UBRELVY, QULIPTA, VRAYLAR, MOUNJARO, CRYSVITA, Veozah, AVYCAZ, REXULTI.
Industry payments across NE — which companies pay providers there.
